NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Neurological Disorders and Stroke (NINDS)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 11
Max Age: 70

Referral Letter Required


Population Exclusion(s)


Special Instructions

Currently Not Provided


Muscle Weakness;
Muscular Dystrophy;
Neuromuscular Disease;

Recruitment Keyword(s)



Myotonic Dystrophy Type-1;
Myotonic Dystrophy Type-2

Investigational Drug(s)


Investigational Device(s)




Supporting Site

National Institute of Neurological Disorders and Stroke


Myotonic dystrophy is a long-term genetic disorder that affects muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and cannot relax. Researchers want to find out how various tests for DM1 or DM2 change over 2 years, to help them develop better tests for people with these diseases. Data and samples from this study will be shared with the Myotonic Dystrophy Clinical Research Network (DMCRN) investigators participating in the ongoing Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (ENDDM1) study


To find better ways to assess how myotonic dystrophy type 1 or type 2 affects people.


People ages 11 70 with DM1 or DM2


Participants will have 3 study visits over 2 years. Participants may be admitted to the clinic. Each visit may last up to a week and will include:

Medical history and physical exam

Blood, heart, and pregnancy tests

Questions about their disease

Breathing and muscle tests, including tests of movement, grip, and hand opening

Speech and swallowing exam

Magnetic resonance imaging (MRI). Participants will lie on a table that slides into a cylinder.

A magnetic field and radio waves will take pictures of the body. They may do a task during the scan. They may have a dye injected.

Pictures of chemicals in the brain or muscle taken in an MRI scanner

Thinking and memory tests

Sleep studies. Electrodes placed on the scalp will record the electrical activity of the brain.

Other devices on the body will measure heartbeat, breathing, movement, and oxygen.

Tests of electrical activity of muscles. Participants move their arms and legs with disks stuck on their skin.

Visits may also include:

Exam by a physician expert in stomach and bowel disorders

A piece of muscle and/or spinal fluid removed by needle

Sponsoring Institute: National Institute of Neurological Disorders and Stroke

--Back to Top--



-Age 11 to 70 inclusive

-Competent to provide informed consent and assent (consent of a parent or guardian will be required for pediatric participants)

-Positive genetic test for DM1 or DM2 (Genetic testing for DM1 or DM2 may be determined after enrollment


-Concurrent enrollment in a clinical trial or participation in an investigative drug trial within 6 months of study entry.

-Concurrent pregnancy or planned pregnancy during the course of the study.

-Concurrent medical condition that would, in the opinion of the investigator or clinical evaluator, compromise performance on study measures:

-Clinically significant infections or medical illness within 30 days from study entry.

-History of, or abnormal laboratory values indicative of, significant medical, neurologic (other than DM1 or DM2), or psychiatric disorders.

-A recent history (30 days prior to study entry) of any of the following conditions on routine blood screening: white blood cells < 3000, platelets < 100,000, hematocrit < 30%, symptomatic liver disease with serum albumin < 3 g/L, or creatinine > 1.5 mg%.

-Any of the following medical conditions: uncontrolled or insulin-dependent diabetes mellitus, congestive heart failure, symptomatic cardiomyopathy, symptomatic coronary artery disease, cancer (other than skin cancer) within 5 years from study entry, multiple sclerosis, or other serious medical illness.

-Other diseases that mimic the signs or symptoms of DM1 or DM2. Coexistence of other neuromuscular disease.

-Thyroid dysfunction that is untreated (if on thyroid hormone replacement therapy, need to have adequate and stable replacement over the previous 6 months from study entry).

-Second or third degree heart block, atrial flutter, atrial fibrillation, ventricular tachycardia, or is receiving medication for the treatment of cardiac arrhythmia.

-Liver or kidney disease requiring ongoing treatment.

-Have a seizure disorder.

-Drug or alcohol abuse within 3 months of study entry (DSM-V criteria will be used for the diagnosis and level of a substance use disorder:

-Treatment with supplemental anabolic hormones (including testosterone, human recombinant growth hormone, human recombinant insulin like growth factor-1, other anabolic drug mixtures) during the previous 12 months from study entry.

Note: non-ambulatory participants are not excluded but are limited to <15% of enrollment. Individuals using a cane or walker will not be examined for gait, balance and mobility.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Ami K. Mankodi, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)

Vanessa J. Ndege
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health
Building 10
Room 2B51A
10 Center Drive
Bethesda, Maryland 20892
(301) 435-9319

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: 1-866-411-1010

Clinical Trials Number:


--Back to Top--